Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
2.65
USD
-1.12%
-9.25%
+167.00%
This article is reserved for members
Not a member ?
Free registration
JonesTrading Starts Rezolute With Buy Rating, $10 Price Target
Apr. 18
MT
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia
Mar. 06
CI
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
Feb. 13
CI
Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer
Jan. 24
CI
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Jan. 23
CI
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema
Dec. 13
CI
JMP Securities Adjusts Price Target on Rezolute to $7 From $8, Maintains Market Outperform Rating
Nov. 14
MT
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
Nov. 13
CI
Rezolute Announces Further Evidence of RZ358?s Efficacy in Tumor-Mediated Hyperinsulinism
23-10-11
CI
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
23-09-14
CI
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023
23-09-14
CI
Cantor Fitzgerald Adjusts Price Target on Rezolute to $5 From $7, Maintains Overweight Rating
23-06-28
MT
Rezolute to Start Late-Stage Study in Congenital Hyperinsulinism in Europe, Other Places
23-06-27
MT
Transcript : Rezolute, Inc. - Special Call
23-06-27
Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358
23-06-27
CI
Transcript : Rezolute, Inc. - Shareholder/Analyst Call
23-05-25
Canaccord Genuity Adjusts Price Target on Rezolute to $17 From $16, Maintains Buy Rating
23-05-19
MT
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
23-05-11
CI
Rezolute, Inc. Announces KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
23-03-23
CI
Transcript : Rezolute, Inc. - Special Call
23-03-22
HC Wainwright Trims Price Target on Rezolute to $17 From $21, Maintains Buy Rating
23-02-14
MT
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
23-02-10
CI
Rezolute Initiates Phase 2 Study of Treatment for Diabetic Macular Edema
22-12-15
MT
Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema
22-12-15
CI
Earnings Flash (RZLT) REZOLUTE Reports Q1 Loss $-0.19
22-11-09
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Companyâs lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
More about the company
Last Close Price
2.65
USD
Average target price
9.667
USD
Spread / Average Target
+264.78%
Consensus
1st Jan change
Capi.
+167.00% 106M +7.52% 113B +11.38% 106B +0.64% 22.27B -12.64% 22.22B -4.04% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**